German cancer antibody biotech eyes SPAC as route to Nasdaq

Title

German Antibody Biotech Veraxa Pursues $1.6B Nasdaq Listing via SPAC Merger

Veraxa, a German antibody biotech focused on cancer therapies, is going public on the Nasdaq through a merger with Voyager Acquisition Corp., a special purpose acquisition company (SPAC)1 5.
The merger values Veraxa at approximately $1.6 billion on a pro forma equity basis4 5.
Upon completion of the deal, Veraxa will have access to up to $253 million in cash from Voyager’s trust and plans an additional financing round to further bolster its R&D efforts1 5.
Veraxa’s main clinical candidate, VX-A901, is an Fc-enhanced antibody targeting FLT3, currently in a phase 1 trial for leukemia1 5. This asset was acquired in 2024 following Veraxa’s purchase of Synimmune5.
The company’s pipeline leverages its Bi-Targeted Antibody Cytotoxicity platform to design next-generation therapies for solid tumors1.
Veraxa is actively developing bispecific antibody drug conjugates (ADCs) and T cell engagers—two high-growth areas in cancer research—with ambitions to have three drugs in the clinic and an expanded portfolio of licensed assets by 20291.
The newly formed public entity will trade under the ticker symbol VERX upon finalization, expected in the fourth quarter of 20255.
The deal provides Veraxa with expanded access to US capital markets as it accelerates its oncology development programs5.